Franz Hefti, co-director of the Lilly Institute for Genetic Medicine and CEO of Lilly sub Prevail
Lilly breaks the bank on the potential for RNA with $700M investment in Boston's Seaport
In the latest boom across drug R&D, Big Pharma has dumped billions into research for RNA-based therapies, betting big on the future in that space …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
